7/107 sources · 6 publishersUpdated Nov 6, 10:08 UTC
Artivion posts Q3 loss, narrows 2026 revenue outlook and confirms NEXUS launch
Artivion reported third‑quarter 2026 revenue of $123.8 million, a 9% year‑over‑year increase, and a net loss of $7.9 million. Adjusted EBITDA fell 8% to $22.5 million. The company narrowed its full‑year 2026 revenue guidance to $484 million‑$492 million and adjusted EBITDA guidance to $93 million‑$98 million, and said the NEXUS aortic device is slated for U.S. commercial launch in January 2027.
Why it matters
Canaccord lowered its price target on Artivion to $30 from $40, citing the tighter revenue guidance. The narrowed outlook may affect investor expectations for growth and valuation.
Key facts
- 1Q3 2026 revenue was $123.8 million, up 9% on a GAAP and constant‑currency basis versus the prior year. prnewswire.com
- 2Net loss for the quarter was $(7.9) million, or $(0.16) per fully diluted share. prnewswire.com
- 3Adjusted EBITDA declined 8% to $22.5 million. prnewswire.com
- 4Full‑year 2026 revenue guidance was narrowed to a range of $484 million to $492 million. prnewswire.com
- 5Full‑year 2026 adjusted EBITDA guidance was narrowed to $93 million to $98 million. prnewswire.com
- 6The company plans to launch its NEXUS aortic device in the United States in January 2027. prnewswire.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.